Services
Evidence, Access & Pricing
Our team of experts works across functions to develop locally nuanced and comprehensive global strategies spanning evidence, value, access and pricing.
The pharma-biotech landscape is rapidly evolving, creating a range of challenges for manufacturers who need to generate evidence, communicate value, and optimize their products’ pricing and access.
Trinity’s Evidence, Value, Access and Pricing team team has unparalleled experience across geographies and therapeutic areas. We work across the product lifecycle, addressing needs at a global & local level.
The Trinity Difference:
- An integrated approach across all offerings and areas of Evidence, Value, Access, and Pricing expertise
- In-depth therapeutic area and product modality experience, including cell and gene therapies
- Scientifically rigorous methodologies and real-world studies to drive impactful evidence and publications
- Compelling real-world data analytics and modeling expertise
- Deep market access expertise, leveraging extensive knowledge of access trends / policy changes
- Global list and net pricing methodological expertise, including in-depth U.S. payer / provider contracting
- First-hand negotiation experience translated into both our strategies and our negotiation training program
Products
We have supported the evidence, value, access & pricing strategy of the majority of innovative launches over the last decade, and have experience spanning across most therapeutic areas.
Experts
Our team consists of experts with in-depth local knowledge and native language skills that contribute towards the development of Trinity’s Geo-Knowledge Resource Hubs which span across all major geographies.
Network
We have an extensive in-house payer network, and access to key stakeholders ranging from national government authorities to local hospital and practice administrators / executives.
Impact
We have a vast portfolio of successful evidence generation and value demonstration studies which have translated into access and commercial success.
Geo-Knowledge Resource Hubs
Trinity’s Geo-Knowledge Resource Hubs distill deep market knowledge, cultivate best practices, and generate thought leadership.
Centers of Excellence
Cell and Gene Therapy
Cell and gene therapies (CGTs) represent the next major breakthrough in the development of innovative treatments for severe diseases, with the possibility to address the root causes of disease and provide lasting clinical value, and in some cases, a cure.
Digital Therapeutics and Health Technology
Digital health technologies are evolving rapidly and are playing an increasingly significant role in both the companion diagnostic and treatment paradigms. Trinity’s experts draw upon their deep understanding of access and reimbursement decision-making for traditional therapeutics to identify and analyze the most impactful events and landscape shifts in the digital space.
Latest Evidence, Value, Access and Pricing Intelligence
Annual State of Global Market Access
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]
Evidence Generation in a Post-IRA World
Since the passage of the Inflation Reduction Act (IRA) in 2022, the pharmaceutical industry has significantly altered how they approach and plan for evidence generation activities to best support product launches and pricing and access negotiations. Leading life science companies are taking proactive steps to adjust how and when they develop evidence and how they […]
The Implementation Game: The Inflation Reduction Act Medicare Drug Price Negotiation Program Guidance
Trinity’s Take Introduction Since the Inflation Reduction Act (IRA) was signed into law in August 2022, biopharma stakeholders have noted the high likelihood of the legislation being challenged in court alongside many questions about how some of the new CMS programs would function. The Medicare Drug Price Negotiation Program is one IRA program expected to […]
Priced Out: Generic Therapy Price Competition and Drug Shortages
Introduction In the summer of 2023, many oncologists and cancer patients faced an impossible choice. Amidst many challenging treatment decisions, they had to determine how to proceed without two mainstays among oncology therapeutics: cisplatin and carboplatin. While it can sometimes be expected that there may be delays for the newest and most innovative treatments to […]
Generating Robust Insights to Develop a Compelling Value Story with RWE
The unprecedented availability of rich RWE data sources gives HEOR, Value and Access and Medical leaders the opportunity to be more intentional than ever before. High-quality, compelling evidence is now a necessity, not just for high-value therapies playing in the rare disease space—but also more broadly, to show reduced unmet needs, health care resource utilization […]
Meet our Evidence, Value, Access and Pricing Experts
Monica Martin de Bustamante
Senior Partner &
Head of Advisory
Monica’s career has focused on pharmaceutical global pricing and market access issues for biopharmaceutical and pharmaceutical products. Her time has been apportioned between the mature and emerging markets, with deep expertise in the U.S., EU5, CAN and JPN. Monica has worked across the major therapeutic areas (oncology, cardiovascular, neurology, metabolic, autoimmune, gastrointestinal, respiratory, etc.) collaborating […]
Valeria Boers Trilles
Director,
Value, Access & Pricing
Ms. Boers is a Director in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Ms. Boers was part of the CBPartners team and focused her experience on pricing and market access engagements, proving strategic support to optimize value communication, product positioning, IRP-based launch sequence and pricing opportunity across a range of therapeutic areas, […]
Christian Frois
Partner,
Value, Access & Pricing
Christian is a recognized and widely published expert on pricing, contracting, market access and payer evidence strategy. He leads Trinity’s pricing, market access, reimbursement and contracting (PARC) group, and has supported the development of PARC strategies for more than 50 assets in the US and ex-US.
Andrew Gould
Partner,
Value, Access & Pricing
Andrew is a Partner in Trinity’s Value, Access and Pricing practice and has over 15 years working within the Life Sciences arena. Prior to joining Trinity, he led CBPartners’ U.S. Center of Excellence and focused on managed markets strategy engagements. His experience has emphasized the development of numerous pricing and access strategies for both pre-launch […]
John Greenaway
Partner,
Value, Access & Pricing
John has 25 years of consulting experience and is currently a leadership team member within Trinity’s Evidence, Value, Access and Pricing (EVAP) practice. John is an expert in U.S. Reimbursement and Contracting where he focuses on Market Access Strategy through Managed Care and Provider / GPO Contract Strategies and sustainable contract structure and design. In […]
Nandini Hadker
Partner,
Evidence Strategy
An economist by training, Nandini is a Partner at Trinity Life Sciences with over two decades of experience in custom research and strategy consulting. She is an expert at helping clients identify what real-world evidence will “move the needle” and drive their product’s success, generating that evidence using publication-grade research, and pulling the insights through […]
Max Hunt
Partner,
Value, Access & Pricing
Max is a Partner in Trinity’s Evidence, Value, Access and Pricing (EVAP) practice. His experience as a global life sciences strategy consultant spans all stages of product development and a wide range of therapeutic areas, including oncology, inflammatory conditions, rare diseases and cell and gene therapies. Over the last decade, Max’s work has spanned a […]
Miguel Martín de Bustamante
Partner,
Value, Access & Pricing
Prior to joining Trinity, Mr. Martín de Bustamante worked across CBPartners’s practices, with a focus on Value, Access, and Pricing. He developed expertise across many related areas, including innovative contracting and access models, strategic product / portfolio positioning, IRP and commercial opportunity based launch sequencing, as well as value positioning across various therapeutic areas. He […]
Matt O’Hara
Partner,
Evidence Strategy
Matt joins Trinity with over 20 years of life sciences consulting experience. During his career, Matt has worked with both pharmaceutical and medical device clients across business/commercial strategy (pricing, market access, product portfolio rationalization, acquisitions, Intellectual Property, and market insights), HEOR (value proposition development, evidence generation planning, and literature reviews, budget impact and comparative effectiveness […]
Bami Oshinowo
Partner, Value, Access & Pricing
& London Office Lead
Prior to joining Trinity, Ms. Oshinowo led engagement work within the Value, Access and Pricing Practice and drove the Early VAP & CP Centre of Excellence at CBPartners. Her primary expertise is on early-stage pipeline issues related to commercial strategy, including competitive positioning, pricing, market access and trial design optimization. Her geographical expertise includes the USA […]
Shinkyu Park
Director,
Evidence, Value, Access & Pricing
Mr. Park is a Director in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Mr. Park’s work at CBPartners was primarily focused on pricing, market access, and value demonstration engagements in support of strategic planning with a variety of biopharmaceutical clients. Mr. Park has led many global (including USA, EU, APAC and LatAm) […]
Julia Pikus
Principal,
Value, Access & Pricing
Julia is a Principal in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Julia led engagement work within the Value, Access and Pricing Practice and drove the Cell and Gene Therapy Centre of Excellence at CBPartners. In this capacity, she supported a range of qualitative and quantitative engagements to inform current and future […]
Greg Berzolla
Managing Director
Greg is a Managing Director in Trinity’s Evidence, Value, Access and Pricing practice, leading the Access Analytics team. Prior to joining Trinity, Greg was a Senior Vice President at Precision, Value and Health. Greg has 30+ years of healthcare consulting and industry experience, including ~20 years of market access and commercial strategy experience. He has […]
Mary Fletcher-Louis
Managing Director &
Head of Value Center of Excellence
Mary brings over 25 years of healthcare and consulting experience to Trinity. She has extensive experience in value strategy and in the development of value communication tools spanning diverse therapy areas. Mary has deep experience of the decision drivers of market access stakeholders across multiple countries and stakeholder types. Fostering a culture of innovation in […]
Arie Grunberg
Principal
Arie is an experienced U.S. Pricing and Market Access strategy consultant with a B.A. in Public Health and a minor in Entrepreneurship & Management from Johns Hopkins University. For almost a decade, Arie has been a trusted partner to his clients, helping them navigate the complex world of Pricing and Market Access. He’s gained valuable […]
If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.